Overview of Novo Nordisk's CEO Has a Comeback Plan
This episode of The Journal examines Novo Nordisk’s effort to rebound after losing momentum in the booming obesity-drug market. CEO Mike Doustdar argues that the company’s initial success with Ozempic and Wegovy helped create a new industry, but that Novo must now adapt faster as Eli Lilly gains share with more effective injectables and as the market shifts toward consumer-like purchasing behavior, oral drugs, and broader “health gains” beyond just weight loss.
What Happened to Novo Nordisk
Novo Nordisk was the first major winner in the weight-loss-drug race, but its lead has eroded as Eli Lilly surged ahead.
- Novo helped launch the obesity-drug boom with Ozempic and Wegovy.
- Eli Lilly’s Zepbound has overtaken Novo in market share and appears more effective in head-to-head weight-loss results.
- Novo’s stock has been hit hard by investor concern over:
- slowing competitive positioning,
- setbacks in pipeline drugs,
- and rapidly changing expectations for the category.
Mike Doustdar’s View of Novo’s Mistakes
Doustdar rejects the idea that Novo simply “messed up,” framing the challenge as the burden of being a pioneer.
Core argument
- Novo was building the market before anyone else had a roadmap.
- Leading in a new category means discovering problems first.
- The company now has to operate in a faster, more consumer-driven environment than it was built for.
Biggest internal lesson
Novo initially treated obesity too much like diabetes:
- diabetes patients tend to think in terms of fear,
- obesity patients often feel shame.
That difference matters because it changes how patients seek treatment, how they engage with healthcare, and how products should be marketed and distributed.
Novo’s New Strategy
Doustdar says Novo is shifting from a purely traditional pharma mindset to a more flexible model that treats patients partly as consumers.
Key strategic changes
- Expand beyond doctor-office prescribing
- Novo learned that many obesity patients prefer e-health / online channels.
- Recognize consumer behavior
- Some patients want treatment but avoid in-person judgment.
- Compete across formats
- Novo wants to win with both injections and pills rather than betting on one.
Weight Loss vs. Health Outcomes
One of the episode’s central themes is that the market’s obsession with percentage weight loss may be temporary.
Doustdar’s thesis
Over time, the real differentiator will be:
- heart health
- kidney outcomes
- liver benefits
- stroke prevention
- broader metabolic and long-term health improvements
He argues obesity itself does not directly kill people; it leads to other diseases that do. Novo wants the discussion to move from “how much weight is lost?” to “how much health is gained?”
The CagriSema Setback
Novo’s next-generation obesity drug, CagriSema, suffered a major blow in a head-to-head trial against Lilly’s Zepbound.
Why it mattered
- The trial disappointed investors.
- Novo lost roughly $100 billion in market value in a single day after the results.
- The result reinforced the perception that Lilly was ahead in the injectable race.
Doustdar’s response
He downplays the idea that the trial was a catastrophe:
- Novo still saw strong weight-loss results.
- But the market has become extremely sensitive to small efficacy differences.
- He suggests that today’s share-price reaction may be more dramatic than the long-term clinical difference.
The Wegovy Pill: Novo’s Big Bright Spot
Novo’s oral version of Wegovy has become a major success and an important part of its comeback plan.
Why it matters
- It launched in January and quickly became a major U.S. drug launch.
- It generated more than 1.3 million prescriptions in the first quarter.
- It helped boost Novo’s stock and earnings.
- It gave Novo a scientific edge over Lilly’s rival pill on weight-loss efficacy.
Doustdar’s take
- The pill brings in many new customers who did not want injections.
- Novo believes it now has the first and only peptide-in-a-pill for this category.
- The company sees the oral version as a way to broaden access and meet consumer preference without sacrificing efficacy.
Pricing Strategy: Lower Prices, Broader Access
Novo is cutting U.S. prices for Wegovy and Ozempic starting next year.
Details
- Wegovy: down to $675/month
- Ozempic: about a 35% reduction
- These cuts will reduce margins significantly.
Why Novo is doing it
Doustdar says:
- very few patients pay full list price anyway,
- the U.S. pharma pricing system has become too distorted,
- Novo wants to avoid becoming a pure low-margin volume business while still expanding access.
The balance Novo is trying to strike
- broaden access to more patients,
- keep enough profitability to fund R&D,
- avoid pricing too aggressively before the next wave of innovation is ready.
What’s Next in the Pipeline
Doustdar says Novo has multiple new therapies in development, including:
- a next-generation obesity pill
- drugs that are easier on the stomach
- therapies for obesity-related conditions such as:
- fatty liver disease
- cardiovascular disease
- kidney disease
One notable candidate: UBT251
- A triple agonist acquired from China.
- Early data suggest it may be best in class on several measures.
- Novo hopes it can eventually match or beat Lilly’s higher-end obesity candidates, including retatrutide.
Main Takeaways
- Novo Nordisk is no longer the unchallenged leader in obesity drugs.
- Eli Lilly has taken the lead in injectables, but Novo still has a strong position in oral therapy.
- The company is rethinking how obesity patients behave: they are not just “patients,” but also consumers.
- Novo’s future strategy is built around:
- broader distribution,
- lower prices,
- oral options,
- and a deeper focus on long-term health outcomes.
- Doustdar’s message is that Novo is not trying to return to the old model — it’s trying to build the next one.
Notable Insight
“It will never go back to what it was. You need to move forward.”
That line captures the episode’s central theme: Novo Nordisk’s comeback depends not on restoring its old dominance, but on adapting to a much bigger, faster, and more competitive market than the one it helped create.